377 related articles for article (PubMed ID: 32615660)
21. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.
Chen J; Hu J; Gu L; Ji F; Zhang F; Zhang M; Li J; Chen Z; Jiang L; Zhang Y; Shi R; Ma L; Jia S; Zhang Y; Zhang Q; Liang J; Yao S; Hu Z; Guo Z
Cancer Immunol Immunother; 2023 Feb; 72(2):409-425. PubMed ID: 35925286
[TBL] [Abstract][Full Text] [Related]
22. Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells.
Tokatlian T; Asuelime GE; Mock JY; DiAndreth B; Sharma S; Toledo Warshaviak D; Daris ME; Bolanos K; Luna BL; Naradikian MS; Deshmukh K; Hamburger AE; Kamb A
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091455
[TBL] [Abstract][Full Text] [Related]
23. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy.
Zhang E; Yang P; Gu J; Wu H; Chi X; Liu C; Wang Y; Xue J; Qi W; Sun Q; Zhang S; Hu J; Xu H
J Hematol Oncol; 2018 Aug; 11(1):102. PubMed ID: 30103775
[TBL] [Abstract][Full Text] [Related]
24. Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors.
Ding J; Guyette S; Schrand B; Geirut J; Horton H; Guo G; Delgoffe G; Menk A; Baeuerle PA; Hofmeister R; Tighe R
Oncoimmunology; 2023; 12(1):2182058. PubMed ID: 36875551
[TBL] [Abstract][Full Text] [Related]
25. Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer.
Zhao R; Cui Y; Zheng Y; Li S; Lv J; Wu Q; Long Y; Wang S; Yao Y; Wei W; Yang J; Wang BC; Zhang Z; Zeng H; Li Y; Li P
Front Immunol; 2021; 12():660488. PubMed ID: 34326835
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
Le Q; Castro S; Tang T; Loeb AM; Hylkema T; McKay CN; Perkins L; Srivastava S; Call L; Smith J; Leonti A; Ries R; Pardo L; Loken MR; Correnti C; Fiorenza S; Turtle CJ; Riddell S; Tarlock K; Meshinchi S
Clin Cancer Res; 2021 Oct; 27(20):5718-5730. PubMed ID: 34380639
[TBL] [Abstract][Full Text] [Related]
27. Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression.
Jiang W; Gu G; Zhang Y; Song Y; Shi M; Wang G; Li H; Tao T; Qin J; Li X; Jia H; Jiao F; Xu W; Huang X
Pharmacol Res; 2023 Nov; 197():106942. PubMed ID: 37775021
[TBL] [Abstract][Full Text] [Related]
28. Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer.
Cao B; Liu M; Huang J; Zhou J; Li J; Lian H; Huang W; Guo Y; Yang S; Lin L; Cai M; Zhi C; Wu J; Liang L; Hu Y; Hu H; He J; Liang B; Zhao Q; Zhu K
Int J Biol Sci; 2021; 17(14):3850-3861. PubMed ID: 34671203
[No Abstract] [Full Text] [Related]
29. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
Haas AR; Tanyi JL; O'Hara MH; Gladney WL; Lacey SF; Torigian DA; Soulen MC; Tian L; McGarvey M; Nelson AM; Farabaugh CS; Moon E; Levine BL; Melenhorst JJ; Plesa G; June CH; Albelda SM; Beatty GL
Mol Ther; 2019 Nov; 27(11):1919-1929. PubMed ID: 31420241
[TBL] [Abstract][Full Text] [Related]
30. Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.
Liu XF; Onda M; Schlomer J; Bassel L; Kozlov S; Tai CH; Zhou Q; Liu W; Tsao HE; Hassan R; Ho M; Pastan I
Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2317283121. PubMed ID: 38227666
[TBL] [Abstract][Full Text] [Related]
31. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
[TBL] [Abstract][Full Text] [Related]
32. The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice.
Zhang Q; Liu G; Liu J; Yang M; Fu J; Liu G; Li D; Gu Z; Zhang L; Pan Y; Cui X; Wang L; Zhang L; Tian X
Mol Ther Oncolytics; 2021 Mar; 20():556-568. PubMed ID: 33738341
[TBL] [Abstract][Full Text] [Related]
33. Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer.
Guo J; Zeng X; Zhu Y; Yang D; Zhao X
J Transl Med; 2024 Apr; 22(1):367. PubMed ID: 38637885
[TBL] [Abstract][Full Text] [Related]
34. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD
Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659
[TBL] [Abstract][Full Text] [Related]
35. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
36. Mesothelin-Specific CAR T Cells Target Ovarian Cancer.
Schoutrop E; El-Serafi I; Poiret T; Zhao Y; Gultekin O; He R; Moyano-Galceran L; Carlson JW; Lehti K; Hassan M; Magalhaes I; Mattsson J
Cancer Res; 2021 Jun; 81(11):3022-3035. PubMed ID: 33795251
[TBL] [Abstract][Full Text] [Related]
37. Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor.
Zhang Z; Jiang D; Yang H; He Z; Liu X; Qin W; Li L; Wang C; Li Y; Li H; Xu H; Jin H; Qian Q
Cell Death Dis; 2019 Jun; 10(7):476. PubMed ID: 31209210
[TBL] [Abstract][Full Text] [Related]
38. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
[TBL] [Abstract][Full Text] [Related]
39. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.
Lanitis E; Poussin M; Hagemann IS; Coukos G; Sandaltzopoulos R; Scholler N; Powell DJ
Mol Ther; 2012 Mar; 20(3):633-43. PubMed ID: 22127019
[TBL] [Abstract][Full Text] [Related]
40. Generation of a Novel Mesothelin-Targeted Oncolytic
Froechlich G; Gentile C; Infante L; Caiazza C; Pagano P; Scatigna S; Cotugno G; D'Alise AM; Lahm A; Scarselli E; Nicosia A; Mallardo M; Sasso E; Zambrano N
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33418877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
